NCT01813084View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

AsthmaHealthy Volunteers

Interventions

DRUG

RV1729 single dose

Safety and tolerability of single escalating doses

DRUG

RV1729 matching placebo single dose

Safety and tolerability of single escalating doses

DRUG

RV1729: 14 day repeat dose

Safety and tolerability of repeat escalating doses

DRUG

RV1729 matching placebo: 14 day repeat dose

Safety and tolerability of repeat escalating doses

Trial Locations (2)

NW10 7EW

London

M23 9QZ

Manchester

All Listed Sponsors

lead

Respivert Ltd

INDUSTRY

NCT01813084 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 | Biotech Hunter | Biotech Hunter